专利检索_ .用化学处理使酶失活专利检索_ .用化学处理使酶失活专利检索查询

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
181	Fatty acid amide hydrolase	JP52181298	1997-11-04	JP2001503630A	2001-03-21	ノートンビーギルーラ; ベンジャミンエフクラヴァット; リチャードエイラーナー
(57)【要約】シス−９，10−オクタデセノアミド及びその他の催眠性脂肪酸一級アミドの催眠活性が脂肪酸アミドヒドロラーゼ(FAAH)の存在下の加水分解により中和される。 FAAHによるシス−９，10−オクタデセノアミドの加水分解は、催眠活性を有しない化合物であるオレイン酸の生成をもたらす。 FAAHが単離され、FAAHをコードする遺伝子がクローン化され、配列決定され、組換えFAAHを発現するのに使用された。 FAAHのインヒビターがヒドロラーゼ活性を阻止することが開示される。
182	Thermostable enzyme	JP24099696	1996-08-26	JP3026554B2	2000-03-27	ジョセフレアードウォルター; エドワードバークデビッド; アンソニーゾコーリマイケル
The present invention provides a thermostable enzyme which is reversibly inactivated by chemical modification, characterized in that an incubation of said chemically modified thermostable enzyme in an aqueous buffer at alkaline pH at a temperature less than about 25 DEG C results in no significant increase in enzyme activity in less than about 20 minutes, and wherein incubation of said chemically modified enzyme in an aqueous buffer, formulated to about pH 8-9 at 25 DEG C, at a temperature greater than about 50 DEG C results in at least a two-fold increase in enzyme activity in less than about 20 minutes. The chemically modified thermostable enzyme can be used for the amplification of nucleic acids, whereby the activity of the inactivated enzyme is recovered by an incubation of the reaction mixture at an elevated temperature prior to, or as part of, the amplification reaction.
183	Reversible modification of thermostable enzyme	JP14761899	1999-05-27	JP2000004878A	2000-01-11	IVANOV IGOR; LOEFFERT DIRK; KANG JIE; RIBBE JOACHIM; STEINERT KERSTIN
PROBLEM TO BE SOLVED: To obtain the subject new enzyme e.g. a polymerase, capable of reducing the formation of a non-specific extension product in PCR reaction by reaction between a thermostable enzyme basically under aqueous conditions and a modifying reagent consisting of an aldehyde below a specific temperature. SOLUTION: This enzyme is a new thermostable enzyme produced by reaction between a thermostable enzyme basically under aqueous conditions and a modifying reagent at <50 deg.C, wherein the modifying reagent is an aldehyde expressed by the formula RHC=O (R is H, a 1-10C alkyl, aryl or alkylaldehyde) and in the reaction, the enzyme is modified so as to cause its thermoreversible inactivation. This enzyme can reduce the formation of a non-specific extension product, without any additive operating process, from an oligonucleotide suffering from wrong priming in a polymerase chain reaction(PCR). This enzyme is obtained by incubating, e.g. the DNA polymerase derived from Thermus aquaticus in an aqueous solution of formaldehyde in a water bath at 37 deg.C for 30 min.
184	Method for inhibiting chymopapain and papain enzyme activity using a polysaccharide of animal origin	JP51603097	1996-10-18	JPH11513569A	1999-11-24	ザーファス，シンシア; ターンディン，タン; ティー．マ，ミン; リー，キャサリン
(57)【要約】酵素混合物中のキモパパインまたはパパインの活性は、グリコーゲン、ヒアルロン酸、または脱硫酸化ヘパリンの添加によって阻害される。
185	No- use of pteridine derivatives as synthase inhibitors	JP53001495	1995-05-06	JPH10504023A	1998-04-14	シユミツト，ハーラルト; プフライデラー，ヴオルフガング; ヘニング，ライナー
(57)【要約】本発明は高い一酸化窒素濃度により惹起される疾患の治療用としての、NO−シンターゼ阻害剤である一般式（Ｉ）（式中、ＸはＯ、NHまたはＮ−（C ₁ 〜C ₅ ）−アルカノイルであり、R ³は基-OR ⁴ 、-NR ⁵ R ⁶または-S(O) _m R ⁷でありそしてＲ、R ¹ 、R ² 、R ⁴ 、R ⁵ 、R ⁶ 、R ⁷およびｍは請求項１に記載の意味を有する）で表されるプテリジン誘導体の使用に関する。
186	Anti-AIDS virus agent	JP11649988	1988-05-13	JP2681653B2	1997-11-26	渡伊藤; 茂郎森; 勇菅原

187	Use of the agent to modulate the tyrosine phosphorylation in order to adjust the permeability of a physiological barrier	JP51431495	1994-11-18	JPH09505076A	1997-05-20	スタッドン，ジェイムズ，マイケル; ヘレンクネクト，カート; モーガン，メアリー，ルイーズ; ルービン，リー，ローレンス
(57)【要約】脳血液関門及び他の生理的関門の透過性がタンパク質のチロシンリン酸化の程度により調節（モジュレート）され得る。チロシンタンパク質脱リン酸化を促進する作用物質は脳血液関門の透過性を減少し、リン酸化を促進するものは透過性を増加する。脳血液関門透過性を増加することは中枢神経系への望ましい効果を有する薬を届けるのに有用である；脳血液関門透過性及び他の生理的関門透過性を減少することは、ＣＮＳに望ましからざる化合物が到達することを防止すること及びある臨床状態において有用である。
188	Thermostable enzyme	JP24099696	1996-08-26	JPH09103292A	1997-04-22	DEBITSUDO EDOWAADO BAAKU; UORUTAA JIYOSEFU REAADO; MAIKERU ANSONII ZOKOORI
The present invention provides a thermostable enzyme which is reversibly inactivated by chemical modification, characterized in that an incubation of said chemically modified thermostable enzyme in an aqueous buffer at alkaline pH at a temperature less than about 25 DEG C results in no significant increase in enzyme activity in less than about 20 minutes, and wherein incubation of said chemically modified enzyme in an aqueous buffer, formulated to about pH 8-9 at 25 DEG C, at a temperature greater than about 50 DEG C results in at least a two-fold increase in enzyme activity in less than about 20 minutes. The chemically modified thermostable enzyme can be used for the amplification of nucleic acids, whereby the activity of the inactivated enzyme is recovered by an incubation of the reaction mixture at an elevated temperature prior to, or as part of, the amplification reaction.
189	E. coli sequence-specific acid protease	JP25739988	1988-10-14	JPH02437A	1990-01-05	RICHIYAADO BENJIYAMIN SHITSUKA; DONARUDO RII HORUTSUSHIYU
PURPOSE: To obtain a E. coli sequence-specific acid protease that makes possible cleavage of proteins by culturing E. coli transformed by a specific protein expression vector. CONSTITUTION: This E. coil acid protease, which specifically catalyzes cleavage between adjacent lysine, adjacent arginine, lysine-arginine and arginine-lysine sequences, is obtained by culturing E. coli transformed by a protein-expression vector that contains cytochrome C peroxidase gene (CCP), E. coli promoter, E. coli replication origin and linkage gene component capable of operating drug-tolerant genes of E. coli, thus expressing cytochrome C peroxidase. COPYRIGHT: (C)1990,JPO
190	Anti-aids viral agent	JP11649988	1988-05-13	JPH01287031A	1989-11-17	MORI SHIGERO; SUGAWARA ISAMU; ITO WATARU
PURPOSE: To obtain an anti-AIDS viral agent having extremely strongly mitogenic activity and anti-AIDS viral activity, containing a homopolysaccharide sulfate having specific molecular weight. CONSTITUTION: An anti-AIDS viral agent containing a sulfate of a homopolysaccharide such as schizophyllan, scleroglucan or pendulan having ≤1,000,000 molecular weight (n≤1,544), preferably ≤500,000 (n≤772) as an active ingredient. 2W17wt.% sulfur content of the sulfate develops mitogenic activity and 3W17wt.% sulfur content of the sulfate exhibits anti-AIDS viral activity. To make the molecular weight in the range, an aqueous solution of the polysaccharide is preferably irradiated with ultrasonic wave or treated by high shear force to depolymerize the polysaccharide. COPYRIGHT: (C)1989,JPO&Japio
191	JPH0141319B2 -	JP5639681	1981-04-16	JPH0141319B2	1989-09-05	SEODOA UORUTAA ESUDAASU

192	JPS643477B2 -	JP14639481	1981-09-18	JPS643477B2	1989-01-20	TAKENOCHI TOMOHARU; KAMIMURA AKIRA

193	Animal serum lowered in protease activity and inhibitor activity	JP12221388	1988-05-20	JPS63313578A	1988-12-21	ERIKU PAURU PAAKU

194	Medicinal composition containing reverse transcriptase enzyme inhibitor	JP798887	1987-01-16	JPS62215529A	1987-09-22	HAINO DEIRINGAA; KAARIN MEERINKU

195	JPS6215560B2 -	JP14570179	1979-11-10	JPS6215560B2	1987-04-08	NAITO ATSUSHI; NAKAGAWA FUMIO; OKAZAKI HISAO; TERAHARA AKIRA; IWATO SEIGO; YAMAZAKI MITSUO
A new compound, named "Griseolic acid", and its salts and can be prepared by the cultivation of Streptomyces griseoaurantiacus SANK 63479 (FERM-P 5223). Griseolic acid and its salts inhibit the activity of the enzyme cyclic adenosine monophosphate phosphodiesterase and, as a result of this, have variety of physiological activities and uses.
196	JPS6048521B2 -	JP9953176	1976-08-20	JPS6048521B2	1985-10-28	RICHAADO ARAN EMU PII; DEIBITO JEIMUZU PETEITSUTO

197	Proteolytic agent and hydrolysis of protein	JP9610681	1981-06-23	JPS5726588A	1982-02-12	SUBEN BURANAA OIRUGENSEN

198	Method of selectively deactivating amylase in amylase and protease mixture	JP4087677	1977-04-09	JPS52134091A	1977-11-09	REIMONDO DEII HOEARU

199	JPS5140152B1 -	JP4140969	1969-05-29	JPS5140152B1	1976-11-01

200	新規融合体及びその検出法	JP2017001117	2017-01-13	JPWO2017122815A1	2018-12-13	竹内賢吾; 坂田征士; 冨樫由紀; 藤田直也; 片山量平
がんの新たな原因遺伝子であるポリヌクレオチドを解明し、この知見に基づき、当該ポリヌクレオチド又はそれがコードするポリペプチドの検出方法、前記検出のためのキット及びプライマーセット、前記ポリペプチドの阻害物質のスクリーニング方法、並びに前記阻害物質を含有するがん治療用医薬組成物を提供する。本発明の検出方法では、被験者から得た消化器由来試料中の、RET融合タンパク質又は該融合タンパク質をコードする融合遺伝子、あるいは、NCOA4又はRUFY1融合タンパク質又は該融合タンパク質をコードする融合遺伝子を検出する。

5 6 7 8 9 10 11 12 13 14

该功能需要专业版企业版VIP权限，您可以：